This webpage is for those patients who have agreed to take part in the research study into the proteome of myeloproliferative neoplasms. This is a joint research project, conducted at the University of Lincoln by Dr Ciaren Graham and the United Lincolnshire Hospitals NHS Trust by Dr Ciro Rinaldi. We will use this webpage to publish a summary of our research findings and links to any publications or abstracts generated through-out the study.
This research will study a group of diseases called myeloproliferative neoplasms (MPN), specifically polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis (MF). In 2005, several groups published reports of a mutation in a protein called JAK2 that was common in myeloproliferative neoplasms. This mutation occurs in more than 95% of patients with PV and in 50 – 60% of patients with ET and MF.
To take part in this research study you have been diagnosed with having a myeloproliferative neoplasm, either polycythaemia vera (PV), essential thrombocythaemia (ET) or myelofibrosis (MF). This study aims to study the role of JAK2 in the development of myeloproliferative neoplasms using state of the art techniques that will include mass spectrometry and proteomics. Through studying the role of JAK2 in myeloproliferative disease we hope to advance our understanding of the regulation of myeloproliferative neoplasm cell biology which will improve our ability to design better clinical therapies to treat these diseases.